Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding Trial of HIPEC Docetaxel and Cisplatin in Gynecologic Malignancies
NCT05410483Phase 1Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of docetaxel in ovarian cancer, pseudomyxoma peritonei (PMP), uterine sarcoma and 1 more, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Maximum Tolerated Dose of Docetaxel at 21 days. Status: unknown.
02
Drugs
docetaxel
03
Conditions
ovarian cancerpseudomyxoma peritonei (PMP)uterine sarcomagynecologic neoplasms
Beyond the preview
Go deeper on NCT05410483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410483.